ClinicalTrials.gg
RecruitingNCT05702853Updated Mar 27, 2026

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

A Phase 1/2 interventional study of Cyclophosphamide injection and Fludarabine Injection in B-cell Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Medical University of South Carolina · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies testing cyclophosphamide in Lymphoma, B-Cell — 8 open to participants now, 12 under way, none of them phase 3. Cyclophosphamide · Lymphoma, B-Cell.

Planned enrollment
23rd of 32
27 · median 37
Started
2023
the only one that year
Phase 1/2
7 of 32
3 open now
Primary completion
2026-11
later than 4 of 11 live
Registered
29th of 32
by date

Among the 32 studies testing cyclophosphamide in Lymphoma, B-Cell, this one is the 23rd largest by planned enrollment, is the only one that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 4 of the 11 other live ones, and was the 29th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 32 studies testing cyclophosphamide in Lymphoma, B-Cell are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing cyclophosphamide in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Read the detailed description

Although CD19 CAR T-cell therapy is a dynamic scientific and clinical breakthrough for CD19+ NHL, issues still remain in terms of relapse, toxicity, and availability. This trial will incorporate a CD34 tag (CD34t) into the CAR T-cell construct, thus allowing a more purified CAR T-cell product via CD34 selection. This purification step will hopefully lead to an improvement in safety/toxicity. Furthermore, the issue of CD19 CAR T-cell relapse has been linked to a lack of CAR T-cell fitness. With the knowledge that Th1 T-cell subsets have improved effector function and Th17 T-cell subsets have improved persistence, the investigators plan to expose the collected T-cells to priming conditions that lead to a metabolically enhanced CAR-T cell product akin to a Th1/17 hybrid cell. The investigators hypothesize that these metabolically programmed CD19 CAR-T cells will yield a high- quality product with enhanced persistence and anti-tumor efficacy when purified based on CD34t expression.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia

Keywords

  • NHL
  • CLL
  • SLL
  • CD19
  • CAR-T
  • CD34
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for study participation must meet all of the following criteria:

  1. Disease Related Criteria

    Participants must have histologic confirmation of one of the following:

    1. CD19+ aggressive non-Hodgkin lymphoma including any of the following subtypes

      • Diffuse Large B-cell Lymphoma, not otherwise specified
      • DLBCL, germinal-center B-cell type (GCB)
      • DLBCL, activated B-cell type (ABC)
      • T-cell histiocyte-rich B-cell lymphomas (THRBCL)
      • Primary cutaneous DLBCL, leg type
      • Intravascular large B cell lymphoma
      • EBV+ DLBCL, NOS
      • DLBCL associated with chronic inflammation
      • HHV8+ DLBCL, NOS
      • High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement(double hit lymphoma)
      • High grade B-cell lymphoma, NOS
      • Primary mediastinal B-cell lymphoma
      • B-cell Lymphoma, unclassifiable with features intermediate between DLBCL and Hodgkin lymphoma, as well as with features intermediate between DLBCL and Burkitt lymphoma
      • Follicular lymphoma grade 3B
      • Transformation of indolent lymphoma (i.e. CLL, MZL, FL, Waldenstrom's lymphoma,etc) to -diffuse large B-cell lymphoma
      • Burkitt Lymphoma
      • Lymphomatoid granulomatosis
    2. CD19+ indolent non-Hodgkin lymphoma including any of the following subtypes:

      • Follicular lymphoma (grade 1-3A)
      • Marginal zone lymphoma: Including splenic marginal zone lymphoma, nodal marginal zone lymphoma, and mucosa associated lymphoid tissue (MALT) lymphoma
      • Waldenstrom's Macrogloublinemia
      • Nodular lymphocyte predominant hodgkin lymphoma (with documented CD19 expression)
    3. Mantle cell Lymphoma
    4. Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
  2. Prior Therapy Criteria Prior/Concurrent Therapy Related Criteria (dependent upon subtype - see below)

    1. Aggressive lymphoma: patients will qualify if any of the following scenarios are met below (radiation does not count as a )

      • Relapse or persistent disease after ≥ 2 lines of systemic therapy OR
      • disease or relapse within 12 months of completion of 1st line systemic therapy OR
      • Refractory disease or relapse ≥ 1 line of therapy but not a candidate for stem cell transplant
      • Patients with Burkitt lymphoma will qualify after ≥ 1 line of therapy regardless of the timing of relapse
    2. Indolent lymphoma:

      • Relapse or persistent disease after ≥ 2 lines of systemic therapy. (Neither single agent rituximab or radiation qualify as a line of therapy.)
    3. Mantle cell lymphoma:

      • Relapse or persistent disease after ≥ 1 line of systemic therapy. Neither single agent rituximab or radiation qualify as a line of therapy.
    4. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

      • Evidence of progression or intolerance after ≥ 2 lines of therapy. The following will qualify as a line of therapy for CLL/SLL:

        • systemic chemoimmunotherapy (e.g. BR, FCR, etc),
        • BTK inhibitor, BCL-2 inhibitor,
        • or PI3 Kinase inhibitor.
        • Neither single agent rituximab/obinutuzumab or radiation qualify as a line of therapy.
  3. Clinical/Laboratory Criteria

    1. Participants must be at least 18 years old
    2. Participants must have a performance status of 0-2 on the scale
    3. Participants must have adequate caregiving support for CAR T-cell therapy as determined by the PI/Co-I.
    4. Participants must have on cross section imaging by PET-CT and/or CT scans alone that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions as defined by IWG criteria. If participants with CLL do not have measurable disease on imaging, a bone marrow showing > 5% CLL involvement in the bone marrow will qualify for enrollment
    5. Participants that have received prior CD19 targeted therapy in the past they must have a tissue biopsy after completion of CD19 targeted therapy noting CD19 expression by either flowcytometry or immunohistochemistry (IHC). CD19 expression must be sufficient per PI/Co-I
    6. Adequate organ function

      • Bone marrow function as evidenced by the following (unless directly attributable to disease within the bone marrow) within 14 days prior to registration.

        • count ≥ 50,000 cells/mm3
        • ≥ 750 cells/mm3
        • Absolute lymphocyte count ≥ 150 cells/ mm3
      • Hepatic function as evidenced by the following within 14 days prior to registration.

        • Serum ≤ 1.5 X unless attributed to Gilbert's syndrome or hemolysis or lymphoma involvement
      • Cardiac

        • No findings per PI/Co-I
      • Pulmonary

        • Oxygen saturation > 90% on room air
      • Renal function as evidenced by the following within 14 days prior to registration.

        • Serum creatinine ≤ 2 mg/dL or (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min
    7. Participants with virus infection must have undetectable viral load and on suppressive therapy within 14 days prior to registration and no evidence of HBV related hepatic damage.
    8. Participants with infection must have complete eradication therapy completed, have no evidence of HCV related damage and have undetectable viral load within 14 days of registration.
    9. Participants with known (HIV)-infection must be receiving anti- retroviral therapy and have an undetectable viral load test within 14 days prior to registration.
    10. should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment. All men and women of childbearing potential must use acceptable methods of throughout the study as described below. FCBP must have negative serum or urine pregnancy within 7 days prior to registration.
    11. Men with female partners who are of childbearing potential: Recommendations for male and partner to use at least two effective contraceptive methods, as described above, during the study.
    12. Participants are able to understand and voluntarily sign consent prior to any study related assessments or procedures are performed.

Exclusion criteria

Exclusion Criteria:

Participants eligible for study participation CANNOT meet any of the following criteria:

  1. Prior/Concurrent Therapy Related Criteria Guidelines regarding when lymphoma directed therapy should be stopped prior to leukapheresis, lymphodepleting chemotherapy, and CAR T-cell infusion are detailed in the protocol. These criteria must be planned to be met for all patients.
  2. Clinical/Laboratory Criteria

    1. Women who are pregnant or breast-feeding.
    2. Participants with active CNS lymphoma. Participants can have a history of active CNS lymphoma as outline in protocol
    3. Participants with evidence of Graft vs Host Disease from stem cell transplant are ineligible unless it is either grade 1 involvement of the skin or not requiring systemic .
    4. Participants with uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
    5. Participants with a history of stroke or intracranial hemorrhage within 6 months prior to registration. Any CNS disorder that would serve as a major barrier in evaluating neurotoxicity/ICANS per enrolling physician
    6. Participants with prior history of other than lymphoma unless subject is free of disease for more than 1 year from signing consent. Exceptions include the following:

      • Basal cell carcinoma of the skin
      • Squamous cell carcinoma of the skin
      • Carcinoma in situ of the cervix or breast
      • Previously treated localized prostate cancer with normal PSA levels
    7. Participants with primary immunodeficiency or history of disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 1 year.
    8. Participants with receipt of within 28 days prior to registration.
    9. Participants with history of autologous stem cell transplant within the last 60 days or allogeneic stem cell transplant within the last 90 days or CAR T-cell therapy within the last 180 days.
    10. Participants with a history of severe immediate reaction to any of the agents used in the study
    11. Participants with any other illness that in the opinion of the investigator, would exclude the patient from participating in this study.
    12. Participants must not have evidence of active CNS lymphoma involvement. This includes parenchymal, spinal cord, meningeal, or cerebrospinal fluid involvement. Patients with history of CNS involvement must have documented remission by contrast-enhanced MRI imaging and CSF evaluation for at least 60 days prior to registration.
    13. Patients must not have any unstable angina, or myocardial infarction within the last 6 months, or symptoms consistent with CHF classification III or IV
    14. Participants with receipt of live vaccine within 28 days prior to registration.
    15. Participants with history of autologous stem cell transplant within the last 60 days or allogeneic stem cell transplant within the last 90 days or CAR T-cell therapy within the last 180days.
    16. Participants with a history of severe immediate hypersensitivity reaction to any of the agents used in the study
    17. Participants with any other illness that in the opinion of the investigator, would exclude the patient from participating in this study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    1 x 10\^6 transduced T cells/kg (± 20%)

    Drug: Cyclophosphamide injection · Drug: Fludarabine Injection · Biological: CD19-CD34t metabolically programmed CAR transduced T-cells

  • Experimental
    Dose Level 2

    1.5 x 10\^6 transduced T cells/kg (± 20%)

    Drug: Cyclophosphamide injection · Drug: Fludarabine Injection · Biological: CD19-CD34t metabolically programmed CAR transduced T-cells

  • Experimental
    Dose Level 3

    2 x 10\^6 transduced T cells/kg (± 20%)

    Drug: Cyclophosphamide injection · Drug: Fludarabine Injection · Biological: CD19-CD34t metabolically programmed CAR transduced T-cells

Interventions

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3

  • DrugFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3

  • BiologicalCD19-CD34t metabolically programmed CAR transduced T-cells

    Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping

06

What researchers measure

Primary outcomes

  1. MTD/MAD/RP2D evaluation

    Maximum tolerated dose (MTD), maximum administered dose (MAD) and the recommended phase 2 dose (RP2D) of CD19-CD34t metabolically programmed CAR T-cells

    Time frame: 12 months

  2. CRS occurrence evaluation

    Rate of grade 3 or higher cytokine release syndrome(CRS)

    Time frame: Duration of study, up to 24 months

  3. ICANS occurrence evaluation

    rate of grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS)

    Time frame: Duration of study, up to 24 months

Secondary outcomes

  1. Overall response and complete remission rate

    1\. Anti-tumor activity of CD19-CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell NHL or CLL/SLL based on overall response rate (ORR) and complete remission (CR) rate. The response rate for patients with NHL will be determined by the 2014 Lugano IWG criteria. The response rate for CLL/SLL patients will be determined by the 2018 iwCLL criteria

    Time frame: 12 months

  2. Progression free survival, duration of response, overall survival evaluations

    Anti-tumor activity of CD19-CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell NHL or CLL/SLL based on progression free survival (PFS), duration of response (DOR), and overall survival (OS)

    Time frame: 12 months

  3. ORR and CR evaluation at the RP2D

    Anti-tumor activity of CD19-CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell NHL or CLL/SLL treated at the RP2D based on ORR and CR rate. The response rate for patients with NHL will be determined by the 2014 Lugano IWG criteria. The response rate for CLL/SLL patients will be determined by the 2018 iwCLL criteria

    Time frame: Duration of study, up to 24 months

  4. PFS, DOR and OS evaluation at the RP2D

    Anti-tumor activity of CD19-CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell NHL or CLL/SLL treated at the RP2D based on PFS, DOR and OS.

    Time frame: Duration of study, up to 24 months

  5. Safety evaluation at the RP2D

    Safety of CD19-CD34t metabolically programmed CAR T-cells at the RP2D, including all grade incidence of CRS and ICANS

    Time frame: Duration of study, up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 52 non-industry phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 82. This study's planned 36 months is below that.

Counting every sponsor, half of 94 studies reached it within 71 months; a quarter within 55 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Jan 27, 2023
StartActual
Nov 6, 2023
Primary completionEst.
Nov 6, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05702853
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Nov 6, 2023
Primary completion
Nov 6, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

HCC Clinical Trials Office
Contact
hcc-clinical-trials@musc.edu
843-792-9321
Brian Hess, PHD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine

Start the discussion